Marta Vera
Norgestion
ONCOMATRYX BIOPHARMA SL
Deal Type
Fundraising
Sector
Healthcare
Completion Date
23rd December 2018
Deal Value
€9m
Company Background
Oncomatryx therapeutic approach is focused on the development of novel precision drugs that target proteins located in the tumor microenvironment. A novel route to cancer treatment, directed not against tumor epithelial cells, but the stromal cells that promote their invasiveness, immune suppression and drug resistance.
Deal Summary
NORGESTION acted as financial advisor to the shareholders of ONCOMATRYX in a successful capital raising with the objective of initiating the clinical trials of a new drug against lung and pancreatic cancer.
Value Added
The challenge was to find the right investors to fit with the shareholders of the company for the future development of ONCOMATRYX and to close the deal within 2018.
